Drug
TLL018 tablets
TLL018 tablets is a pharmaceutical drug with 4 clinical trials. Currently 1 active trials ongoing. Historical success rate of 100.0%.
Total Trials
4
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Clinical Success Rate
100.0%
Based on 3 completed trials
Completion Rate
100%(3/3)
Active Trials
1(25%)
Results Posted
0%(0 trials)
Phase Distribution
Ph phase_1
2
50%
Ph phase_3
1
25%
Ph phase_2
1
25%
Phase Distribution
2
Early Stage
1
Mid Stage
1
Late Stage
Phase Distribution4 total trials
Phase 1Safety & dosage
2(50.0%)
Phase 2Efficacy & side effects
1(25.0%)
Phase 3Large-scale testing
1(25.0%)
Highest Phase Reached
Phase 3Trial Status & Enrollment
Completion Rate
100.0%
3 of 3 finished
Non-Completion Rate
0.0%
0 ended early
Currently Active
1
trials recruiting
Total Trials
4
all time
Status Distribution
Active(1)
Completed(3)
Detailed Status
Completed3
Recruiting1
Development Timeline
Analytics
Development Status
Total Trials
4
Active
1
Success Rate
100.0%
Most Advanced
Phase 3
Trials by Phase
Phase 12 (50.0%)
Phase 21 (25.0%)
Phase 31 (25.0%)
Trials by Status
completed375%
recruiting125%
Recent Activity
1 active trials
Showing 4 of 4
recruitingphase_3
A Study of Efficacy and Safety of TLL-018 in CSU Participants
NCT06396026
completedphase_2
The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis
NCT05772520
completedphase_1
Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria.
NCT05373355
completedphase_1
Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis
NCT05342428
Clinical Trials (4)
Showing 4 of 4 trials
NCT06396026Phase 3
A Study of Efficacy and Safety of TLL-018 in CSU Participants
NCT05772520Phase 2
The Efficacy and Safety of TLL018 in Moderate-to-severe Plaque Psoriasis
NCT05373355Phase 1
Safety and Efficacy of TLL018 in Patients With Chronic Spontaneous Urticaria.
NCT05342428Phase 1
Safety and Efficacy of TLL018 in Patients With Plaque Psoriasis
All 4 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 4